Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC

Adicet Bio, Inc.

ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.
ADI-001 additional autoimmune indications: Phase 1 enrollment to start Q1 2025 for SLE, systemic sclerosis, IIM, stiff person syndrome; preliminary data H2 2025.
ADI-270 ccRCC Phase 1: 3 patients enrolled; first dosed Dec 2024; ~7 sites activated; preliminary data expected H1 2025.
ANCA-associated vasculitis enrollment planned for H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.